15th week of 2012 patent applcation highlights part 31 |
Patent application number | Title | Published |
20120087899 | Heparan Sulphate - Heparan sulphate from bone marrow stroma is disclosed together with the use of heparan sulphate from bone marrow stroma in the differentiation and/or lineage commitment of stem cells. | 2012-04-12 |
20120087900 | IMMUNOTHERAPEUTIC AGENT - The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an IL-2 gene or a water-soluble TGF-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy. | 2012-04-12 |
20120087901 | Engineered Mesenchymal Stem Cells and Methods of Using Same to Treat Tumors - This invention provides a method for treating a subject afflicted with a tumor using genetically modified mesenchymal stem cells, wherein each genetically modified mesenchymal stem cell contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter/enhancer combination, whereby the cytotoxic protein is selectively expressed when the genetically modified mesenchymal stem cells come into proximity with the tumor's stromal tissue. This invention further provides genetically modified mesenchymal stem cells for use in this method. | 2012-04-12 |
20120087902 | Therapeutic Use Of Probiotics - The involvement of intestinal microbiota in the initiation and perpetuation of inflammatory bowel disease is widely accepted. To reestablish the homeostasis of the gut the use of probiotics has been proposed, with however, limited clinical benefit. This invention relates to an assay based on the modulation of the immunological activity in DCs (dendritic cells) by probiotic strains, in particular | 2012-04-12 |
20120087903 | Hair growth agent having a platelet dry powder - A hair growth agent having an effective dose of a platelet dry powder and a pharmaceutically acceptable solvent and/or excipient, wherein the effective dose refers to the presence of at least 1,000 platelets in every milligram of the hair growth agent. | 2012-04-12 |
20120087904 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer - The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer. | 2012-04-12 |
20120087905 | TREATMENT OF DISEASES RELATED TO HYPERACTIVITY OF THE COMPLEMENT SYSTEM - Raising the level of Factor I above physiological levels can be used to treat diseases in which the underlying pathology is linked to overactivity of the C3b-feedback cycle and the generation and pro-inflammatory effects of iC3b. Methods, agents, and compositions for treatment of such diseases are described. | 2012-04-12 |
20120087906 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 2012-04-12 |
20120087907 | PROTHROMBIC COMPLEX COMPOSITION - The present disclosure relates to a method for preparing a composition or a concentrate of a prothrombic complex that includes the II, VII, IX and X coagulation factors, including providing a supernatant of a plasma cryoprecipitate, applying the supernatant on an anion-exchange resin for producing an eluate containing the complex and proteins having a high molecular weight, and applying the eluate on a hydroxyapatite column for producing a second eluate containing the complex. The disclosure also relates to a composition that can be produced by the method. | 2012-04-12 |
20120087908 | FACTOR VII COMPOSITION - The invention relates to a stable pharmaceutical composition in liquid form or in solid form, comprising factor VII, said composition being free of mannitol and of sucrose, or even also of any antioxidant. | 2012-04-12 |
20120087909 | NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS - The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention. | 2012-04-12 |
20120087910 | SPARC ANGIOGENIC DOMAIN AND METHODS OF USE - The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain. | 2012-04-12 |
20120087911 | CRYSTAL STRUCTURE - This invention relates to a crystallisable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications. | 2012-04-12 |
20120087912 | TREATMENT METHODS USING DKK-1 ANTIBODIES - The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed. | 2012-04-12 |
20120087913 | INDUCTION OF TUMOR HYPOXIA FOR CANCER THERAPY - Methods and compositions for enhancing the ability of hypoxia-activated bioreductive agents to kill tumor cells within solid tumors are provided. Local regions of hypoxia are created within a tumor, or within a region containing a tumor, resulting in enhanced activation of hypoxia-activated bioreductive agents (e.g. tirapazamine) within the local region. The activated hypoxia-activated bioreductive agents kill tumor cells in the hypoxic region by catalyzing DNA stand breakage within the tumor cells. Because the activity is localized, side effects that typically occur as a result of systemic administration of bioreductive agents are reduced. | 2012-04-12 |
20120087914 | INHIBITION OF TRIM62 ACTIVITY REDUCES CANCER CELL PROLIFERATION - The present invention provides methods to treat cancers using inhibitors of the TRIM62 protein and methods to identify inhibitors and other modulators of the TRIM62 protein. Pharmaceutical compositions that contain an inhibitor of a TRIM62 protein are also provided. | 2012-04-12 |
20120087915 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 2012-04-12 |
20120087916 | ANTI-ICAM-1 ANTIBODY, USES AND METHODS - The present invention relates to an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, and to the use thereof in medicine for the treatment of cancers, such as multiple myeloma. | 2012-04-12 |
20120087917 | LOX AND LOXL2 INHIBITORS AND USES THEREOF - The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state. | 2012-04-12 |
20120087918 | METHODS AND COMPOSITIONS FOR INHIBITING THE GROWTH OF HEMATOPOIETIC MALIGNANT CELLS - Disclosed herein are compositions and methods for reducing the growth of hematopoietic malignant cells (e.g., B-cell leukemia cells). The methods involve reducing the growth of hematopoietic malignant cells by contacting hematopoietic malignant cells with GP88 antagonists. GP88 is an 88 KDa autocrine growth factor that promotes the growth of hematopoietic malignant cells. Antagonists to GP88 are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies. Also provided are methods for determining if a patient is responding or is responsive to anti-cancer therapy (e.g., glucocorticoid therapy). Increased levels of GP88 in hematopoietic cells indicates a patient is not responding or responsive to anti-cancer therapy. | 2012-04-12 |
20120087919 | METHOD FOR TREATING DIABETES - Fusion proteins binding specifically to cell types of the islets of Langerhans and delivering therapeutic or prophylactic agents are provided herein, as well as compositions thereof. Methods for treating or preventing diseases related to the pancreas such as diabetes are also disclosed. The therapeutic or prophylactic agents include Nemo-binding domain peptides and other inhibitors of NF-kB activation. | 2012-04-12 |
20120087920 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 2012-04-12 |
20120087921 | NOVEL CHEMOKINE BINDING POLYPEPTIDES CAPABLE OF INHIBITING THE COURSE OF AUTOIMMUNITY, INFLAMMATION AND CANCER - Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions. | 2012-04-12 |
20120087922 | DR5 ANTIBODIES AND USES THEREOF - The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer. | 2012-04-12 |
20120087923 | Antibodies to OPGL - Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described. | 2012-04-12 |
20120087924 | Recombinant B. pseudomallei Adhesin Protein and Methods and Uses Thereof - Isolated and/or recombinant adhesin polypeptides from | 2012-04-12 |
20120087925 | METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS - A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1. | 2012-04-12 |
20120087926 | CHICKEN-DERIVED ANTI-LOX-1 ANTIBODY - Anti-LOX-1 antibodies having higher efficiency in action and excellent cross-reactivity are obtained. The anti-LOX-1 antibodies having higher efficiency in action and excellent cross-reactivity have been obtained, the antibodies being which specifically binds to a LOX-1 and having heavy chain CDR3 comprising one or more amino acid sequences selected from the group consisting of a) an amino acid sequence set forth in SEQ ID NO: 1, b) an amino acid sequence having 80% or more homology to the amino acid sequence a), c) an amino acid sequence having one or several amino acid deletions, substitutions, or additions in the amino acid sequence a), and d) an amino acid sequence encoded by a nucleotide sequence of a nucleic acid chain hybridizing under a stringent condition with a nucleic acid chain having a nucleotide sequence complementary to a nucleotide sequence encoding the amino acid sequence a). | 2012-04-12 |
20120087927 | ANTIBODY CONTAINING IGG2 HAVING AMINO ACID MUTATION INTRODUCED THEREIN - The present invention can provide a monoclonal antibody which comprises a heavy chain constant region which is IgG2 wherein valine at position 234, glutamine at position 237 and proline at position 331 are at least substituted with alanine, alanine and serine, respectively (numbering is based on the EU index of Kabat et al); has an agonist activity; and binds to human CD40. | 2012-04-12 |
20120087928 | THERAPEUTICS FOR AGE-RELATED MACULAR DEGENERATION - The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD. | 2012-04-12 |
20120087929 | VEGF Antagonist Formulations for Intravitreal Administration - Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence of residues 27-457 of SEQ ID NO:4. | 2012-04-12 |
20120087930 | Marker of Streptococcus Anginosus/ Streptococcus Constellatus (MOAC) and Uses Thereof - The present invention relates to nucleic acids, vectors and polypeptides that are suitable markers for detecting | 2012-04-12 |
20120087931 | THERAPEUTIC AND DIAGNOSTIC ANTI-HSP70 ANTIBODIES - Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are described. In particular, specific antibodies are provided, which are capable of binding an epitope of Hsp70 that is extracellularly localized on diseased tissue and cells, in particular on tumor cells and infected cells. | 2012-04-12 |
20120087932 | DIAGNOSTIC TEST FOR VIRUS - Unique Avian Nephritis Virus (ANV) nucleic acid sequences have been determined. Primers and probes have been developed using the isolated nucleic acid sequences and a reverse transcription PCR has been developed to detect the presence of ANV in commercial flocks. Furthermore, use of the nucleic acid sequences and amino acids sequences encoded therefrom and antibodies to said amino acids is discussed. | 2012-04-12 |
20120087933 | ENHANCED MSC PREPARATIONS - The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof. | 2012-04-12 |
20120087934 | COADMINISTRATION OF ALPHA-FETOPROTEIN AND AN IMMUNOMODULATORY AGENT TO TREAT MULTIPLE SCLEROSIS - The present invention features methods for treating multiple sclerosis by administering an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents to a patient in need thereof. Also disclosed are compositions and kits that contain an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents. | 2012-04-12 |
20120087935 | SERINE RICH PEPTIDES HAVING ANTIOXIDATIVE STRESS PROPERTIES - The present invention relates to novel serine rich peptides capable of exhibiting antioxidative properties and that can be used to protect a cell, tissues, organs or a multi-cellular organism, such as animals, against oxidative stress. In aspects of the invention, the peptides may be derived from egg yolk proteins utilizing only generally recognized as safe (GRAS) compounds. The invention also relates to cosmetics, functional foods, food supplements or pharmaceutical formulations comprising the peptides of the present invention having antioxidative properties. The cosmetics, functional food or pharmaceutical products are particularly suitable for the care of the skin in protecting against oxidative stress and ageing phenomena. | 2012-04-12 |
20120087936 | THERAPEUTIC AND PROPHYLACTIC VACCINE FOR THE TREATMENT AND PREVENTION OF PAPILLOMAVIRUS INFECTION - Embodiments of the present invention provide compositions including a complexes of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. Other embodiments also provide complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to elicit immune responses in a patient to papillomavirus. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infection, especially papillomavirus infection and cervical cancers and warts associated therewith, made from compositions of this invention, are also disclosed. Nucleic acids and expression vectors coding for compositions are also disclosed. | 2012-04-12 |
20120087937 | NOVEL COMPOSITIONS - This disclosure provides novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease. The constructs are chimeric proteins comprising L1 proteins with an HPV L2 peptide inserted in to the L1 protein. Such chimeric proteins may be formulated into immunogenic e.g., vaccine compositions, and optionally formulated with HPV L1 VLP based vaccines. | 2012-04-12 |
20120087938 | Consensus/ancestral immunogens - The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens. | 2012-04-12 |
20120087939 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING SHIGA TOXIN-PRODUCING ESCHERICHIA COLI INFECTION - Compositions and methods for stimulating an immune response against Shiga toxin-producing | 2012-04-12 |
20120087940 | VECTOR FOR TREATING ALZHEIMER'S DISEASE - The present invention provides methods for efficiently inducing anti-Aβ antibody and methods for preventing and treating Alzheimer's disease. The present inventors successfully induced anti-Aβ antibody in a highly efficient manner by administering an RNA viral vector that expresses a fusion protein between an AB5 toxin B subunit and an Aβ antigen peptide. Administration of the vector resulted in a significant increase of anti-Aβ antibody in plasma, and decrease in the Aβ level in brain tissues and decrease in the anti-Aβ antibody-positive area. The present invention enables more efficient vaccine gene therapy for preventing and treating Alzheimer's disease. | 2012-04-12 |
20120087941 | Compositions of Marine Botanicals to Provide Nutrition to Aging and Environmentally Damaged Skin - Discloses is a topical skin care composition and method for its use comprising | 2012-04-12 |
20120087942 | Compositions of Marine Botanicals to Provide Nutrition to Aging and Environmentally Damaged Skin - Disclosed is a topical skin care composition and method for its use comprising water, | 2012-04-12 |
20120087943 | AGENT FOR PREVENTING ADVERSE SIDE EFFECTS OF CARCINOSTATIC AGENT - The present invention provides a side effect inhibitor of drug therapy for colorectal cancer using 5-fluorouracil, comprising fucoidan or a fucoidan-containing material; a method for inhibiting side effects of drug therapy for colorectal cancer using 5-fluorouracil, which comprises administering fucoidan or a fucoidan-containing material to a colorectal cancer patient; and use of fucoidan or a fucoidan-containing material for the production of a side effect inhibitor of drug therapy for colorectal cancer using 5-fluorouracil. | 2012-04-12 |
20120087944 | ORAL VACCINE FAST-DISSOLVING DOSAGE FORM USING STARCH - A fast-dissolving dosage form (FDDF) for the delivery of a vaccine is prepared using a formulation containing a starch, optionally, along with at least one additional matrix forming agent, preferably, a combination of gelatin and mannitol, wherein an immune response is induced in a patient in need thereof. | 2012-04-12 |
20120087945 | METHOD FOR KEEPING AN IMMUNOGENIC COMPOSITION AVAILABLE FOR ADMINISTRATION TO AN ANIMAL - The present invention pertains to a method for keeping an immunogenic composition available for administration to an animal, wherein said composition comprises an antigen and an emulsion which is a single emulsion at a first temperature below a body temperature of the animal and which emulsion reverses at a second temperature between the first temperature and the body temperature, said method comprising providing the composition, freezing the composition, and storing the frozen composition until it is needed for administration to the animal. The invention also pertains to a method for testing an immunogenic composition, and an immunogenic composition, optionally in combination with specific instructions for storing the composition. | 2012-04-12 |
20120087946 | RECOMBINANT BACTERIUM AND METHODS OF ANTIGEN AND NUCLEIC ACID DELIVERY - The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce an immune response. | 2012-04-12 |
20120087947 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING DERMATITIS - The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis. | 2012-04-12 |
20120087948 | PARTICULATE CARTILAGE SYSTEM - The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions. | 2012-04-12 |
20120087949 | OLIGONUCLEOTIDE MICELLES - The present invention provides homogenous populations of micelles, methods for preparing these populations, methods for treating or preventing a disease or disorder using the population of micelles of the invention. | 2012-04-12 |
20120087950 | FUNCTIONALIZED CALCIUM PHOSPHATE ARTIFICIAL BONE AND JOINT COMPOSITIONS AND METHODS OF USE AND MANUFACTURE - The present invention provides a functionalized composition and resulting functionalized body or prosthesis for in vitro and in vivo use comprising at least one calcium phosphate containing phase that is functionalized with a linker group comprising at least one of an organic acid molecule, a phosphonic acid, an amine, N,N-dicyclohexylcarbodiimide, and 3-maleimidopropionic acid N-hydroxysuccinimide ester, and combinations thereof, and one or more of a chemical and/or a biologically active moieties, wherein the linker group provides for a reactive location for the attachment of the chemical or biologically active moiety, or both, to the calcium phosphate containing phase, and optionally including an unmodified and/or modified calcium aluminate containing phase. The functionalized compositions have a pliable physical property when mixed with water and adhere to natural bone and subsequently harden at ambient temperatures. Methods of manufacturing a functionalized artificial prosthesis that may be used as artificial bones, joints, in-vitro support structures, and in-vivo support structures for cells, tissues, organs, and nerve growth and regeneration are disclosed. Methods of repairing a bone, vertebrae, or tissue structures using the functionalized compositions are provided. | 2012-04-12 |
20120087951 | Fabric with Antimicrobial Properties - A method of producing a fabric with antimicrobial properties that includes liquefying bamboo to produce a slurry, adding an antimicrobial element to the slurry, adding a non-bamboo fiber to the slurry to create a mixture and extruding the mixture to produce a fiber. The antimicrobial fabric may include a composition of 69% bamboo, 30% cotton and 1% silver. | 2012-04-12 |
20120087952 | Pulmonary Delivery in Treating Disorders of the Central Nervous System - A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm | 2012-04-12 |
20120087953 | PHARMACEUTICAL COMPOSITIONS OF ACTIVE PHARMACEUTICAL INGREDIENT COMPRISING SULPHONYLUREA MOIETY WITH EXCELLENT DISSOLUTION PROPERTIES - The present invention provides a pharmaceutical composition comprising at least one active pharmaceutical ingredient comprising sulphonylurea moiety, wherein the at least one active pharmaceutical ingredient comprising sulphonylurea moiety is intimately mixed with a basic agent. The weight ratio of the basic agent and the at least one active pharmaceutical ingredient comprising sulphonylurea moiety is from 2.5:1 to 50:1, preferably from 2.5:1 to 25:1, more preferably from 3.5:1 to 15:1, yet more preferably from 3.5:1 to 10:1. The pharmaceutical composition can be obtained by simply mixing active pharmaceutical ingredient comprising sulphonylurea moiety and the basic agent in the aforementioned weight ratio, optionally in the presence of the granulation liquid. Alternatively, the pharmaceutical composition can be obtained by at least partially or fully dissolving the compounds in the granulation liquid or solvent, and at least partly precipitating them. The invention provides improved dissolution properties of the active pharmaceutical ingredient comprising sulphonylurea moiety. | 2012-04-12 |
20120087954 | ION SUBSTITUTED CALCIUM PHOSPHATE COATINGS - A method for the formation of a surface coating of an ion substituted calcium phosphate on a substrate, the coating itself and the use of the coating. | 2012-04-12 |
20120087955 | NANOPARTICULATE MEGESTROL FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm. | 2012-04-12 |
20120087956 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS RELATED TO LACK OF BLOOD SUPPLY, SHOCK AND NEURONAL INJURIES - A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure. | 2012-04-12 |
20120087957 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUSPENSIONS FOR INHALATION - Process for preparing sterile suspensions for inhalation comprising an active ingredient insoluble in water and wherein at least 80% of the particles of said active ingredient have a diameter between 3 and 5 μm, comprising the following stages: dissolving the active ingredient in the minimum quantity of an alcoholic solvent, optionally in the presence of a polyol and adding at least one surfactant, filtering the solution obtained in the previous stage through a sterilizing filter, adding the solution from stage (b) to sterile water under sonication to directly obtain a suspension wherein the particles have a reduced diameter. | 2012-04-12 |
20120087958 | Multi-Dimensional Biomaterial and Method for Producing the Same - Biomaterial having a multi-dimensional structure and comprising differentiated MSCs tissue and demineralised bone matrix, wherein said demineralised bone matrix is dispersed within the differentiated MSCs tissue, method for producing the same and use thereof. | 2012-04-12 |
20120087959 | NANODISPERSION OF A DRUG AND PROCESS FOR ITS PREPARATION - The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more drugs, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts. | 2012-04-12 |
20120087960 | CATION COMPATIBLE METAL OXIDES AND ORAL CARE COMPOSITIONS CONTAINING THE METAL OXIDES - A cationic compatible metal oxide and oral care compositions containing the metal oxide are disclosed. Preferably, the oral care compositions contain a cationic compatable metal oxide and a cationic ingredient, such as for example, a cationic antibacterial agent such as cetyl pyridinium chloride (“CPC”). The cationic compatible metal oxide, e.g. silica, comprise metal oxide particles having a subtantially negative surface charge and a vitamin deposited onto or reacted with the surface of the metal oxide particles in an amount sufficient to provide a substantially positive surface charge on the metal oxide particle. Processes for making and using the vitamin modified metal oxide in oral care compositions are also disclosed. | 2012-04-12 |
20120087961 | HEPATITIS A VIRUCIDE - The invention relates to agents which combat the hepatitus A virus, containing only minimal amounts of chlorine-containing and/or chlorine cleaving active ingredients, or none of said substances. The inventions also relates to the use of these agents and to a method for their production. | 2012-04-12 |
20120087962 | NOVEL ARTICLE - Aspects of the present invention are directed to personal protection articles, such as protective clothing, articles for sequential contact with multiple users, and cellulosic articles, which have their surface a coating formulation having activity to de-activate pathogenic micro-organisms, the coating comprising an acidic polymer, suitably the polymaleic acid material Gantrez™, a surfactant and an acid. Processes for making such articles, and suitable coating formulations are also disclosed. | 2012-04-12 |
20120087963 | DISINFECTANT COMPOSITION COMPRISING A BIGUANIDE COMPOUND - Disclosed is a method for killing spores from a surface or a material, comprising applying an effective amount of a biocidal composition which comprises one or more biguanide polymers, and one or more further active agents on said surface or material, characterised in that the or each further active agent is, when taken alone, sporicidally inactive. Compositions comprising polymeric biguanides and one or more further biocidal agents and, optionally, a polyorganosiloxane, have been found to be effective as a sporicidal agent and are particularly effective against the spores of | 2012-04-12 |
20120087964 | HIGHLY WETTABLE, WATER DISPERSIBLE, GRANULES INCLUDING TWO PESTICIDES - The present disclosure relates to water dispersible granular pesticide compositions, and methods of making and using the compositions. The pesticide compositions include an inner layer including a first pesticide coated on to a substrate, and an outer layer comprising a second pesticide coated on the inner layer. The outer layer increases the water dispersibility of the granular composition, and protects the first pesticide against hydrolysis and photolysis. | 2012-04-12 |
20120087965 | ANTIMICROBIAL AND ANTIODOR SOLUTIONS AND DELIVERY SYSTEMS - Antimicrobial solutions and delivery systems for them use liquid antimicrobial solutions with: | 2012-04-12 |
20120087966 | ANTIMICROBIAL FOAM - A resilient foam material having an active antimicrobial bound to, incorporated within, and projecting from its surface is provided for incapacitating or destroying microbes. The antimicrobial has an atomic structure that is capable of mechanically piercing or lysing a microbe thereby incapacitating or destroying the microbe. The resilient antimicrobial foam material may be manufactured into a resilient antimicrobial foam product for drawing across a surface and mechanically incapacitating or destroying microbes on the surface. The resilient antimicrobial foam material may be manufactured into a membrane for providing a sterile barrier for a surface. The resilient antimicrobial foam material is manufactured by combining the antimicrobial with a foam polymer material, heating the foam polymer material under pressure to a temperate that does not deactivate the antimicrobial, incorporating a blowing agent, cooling the material, and extruding the material. | 2012-04-12 |
20120087967 | Disinfectant and Sanitizer for Cosmetics and Cosmetic Tools - Disclosed is a disinfecting, sanitizing, and conditioning product which may be applied to cosmetics and cosmetic tools. | 2012-04-12 |
20120087968 | Antimicrobial Packaging Material and Methods of Making and Using the Same - The presently disclosed subject matter is generally directed to packaging materials comprising at least one antimicrobial agent. Particularly, the disclosed packaging materials incorporate, via extrusion into the sealant layer, an antimicrobial agent based on the lauroyl arginate (LAE) moiety. Such packaging materials are suitable for use in the packaging of food products (such as fresh red meat) to control microbial contamination. | 2012-04-12 |
20120087969 | Mu-Conotoxin Peptides and Use Thereof as a Local Anesthetic - In one embodiment, the present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. An embodiment of the invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic. | 2012-04-12 |
20120087970 | Apparatus and Method for Removing Epithelium from the Cornea - An apparatus and a method for removing epithelium from the cornea include a fluid agent for facilitating de-epithelialization of the cornea. A disc includes a biocompatible material operable for covering a predetermined zone of a cornea. The disc is hydrated by the fluid agent, wherein the hydrated disc is pliable for conforming to a surface of the cornea. An application of the hydrated disc to the cornea substantially constrains the fluid agent to the determined zone and softens a corneal epithelium enabling delamination of the epithelium from an underlying stroma. | 2012-04-12 |
20120087971 | CONTACT DRUG DELIVERY SYSTEM - A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed by using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having complexing sites, and cross-linking monomers, which are copolymerized using a suitable initiator. The complexing sites of the recognitive polymeric hydrogel that is formed preferably mimics receptor sites of a target biological tissue, biological recognition, or biological mechanism of action. The system in accordance with an embodiment of the intention is a contact lens for delivering a drug through contact with an eye. | 2012-04-12 |
20120087973 | siRNA MICROBICIDES FOR PREVENTING AND TREATING DISEASES - The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally. | 2012-04-12 |
20120087974 | INCREASED EFFECTIVENESS OF ALLYLAMINE DRUG COMPOUNDS FOR TOPICAL TREATMENT OF FUNGAL INFECTIONS OF THE SKIN AND SKIN APPENDAGES - The present invention provides compositions comprising allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages. In some embodiments a positive charge and enhancers are used in the compositions to allow for increased penetration of the active ingredient through skin and skin appendages. In some embodiments the positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle. The present invention also provides methods for making compositions comprising an allylamine drug compound, and methods of using such compositions for the treatment of fungal infections of the skin and skin appendages. | 2012-04-12 |
20120087975 | Method of Producing A Cationic Liposomal Preparation Comprising A Lipophilic Compound - A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed. | 2012-04-12 |
20120087976 | ADJUVANT COMPOSITIONS COMPRISING A NON-IONIC ISOTONICITY AGENT - The present invention relates to an aqueous adjuvant composition comprising a TLR-4 agonist and a saponin in a liposomal formulation and a non-ionic isotonicity agent having low salt concentrations. | 2012-04-12 |
20120087977 | AQUEOUS CARBONATED MEDIUM CONTAINING AN AMINO(METH)ACRYLATE POLYMER OR COPOLYMER - The invention relates to an aqueous medium containing an amino(meth)acrylate polymer or copolymer which is not soluble in demineralised water, characterized in that the medium has a content of an aqueous phase of at least 60% by weight and a content of up to 40% by weight of solids comprising the amino(meth)acrylate polymer or copolymer, whereby the aqueous phase is charged by a sufficient amount of carbon dioxide that effects the amino(meth)acrylate polymer or copolymer to be present in solute form in the medium. The aqueous medium may be used beneficially as a coating or binding solution for the spray coating or binding of pharmaceutical compositions or nutraceutical compositions or cosmetical compositions. | 2012-04-12 |
20120087978 | DOSAGE FORMS OF APIXABAN - The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, deep vein thrombosis and acute coronary syndrome with said dosage form. | 2012-04-12 |
20120087979 | EXTENDED-RELEASE ORAL DOSAGE FORMS FOR POORLY SOLUBLE AMINE DRUGS - Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling membrane. Such dosage forms allow for the consistent release of the active agent in both gastric pH conditions and in the intestine. Methods of making such dosage forms are also provided. | 2012-04-12 |
20120087980 | STIMULATION OF NEUROREGENERATION BY FLAVONOID GLYCOSIDES - Flavonoid glycosides, such as isoquercitrin, are shown to stimulate the formation of neuritis and neuronal synapses in neurons and neuronal progenitor (stem) cells. | 2012-04-12 |
20120087981 | Skin Engaging Member Comprising Encapsulated Actives - A skin engaging member suitable for use in a hair removal device, said skin engaging member comprising an encapsulated active contained in a matrix material, an encapsulated active comprising at least one nano-particle encapsulated in a micro-particle, wherein said nano-particle comprises a shell comprising a hydrophobic material, and wherein said micro-particle comprises a shell comprising a water sensitive material; and wherein at least one of said nano-particle and said micro-particle comprises a skin care active. | 2012-04-12 |
20120087983 | ORTHOPEDIC APPLICATION OF ENCAPSULATED STEM CELLS - Described herein are orthopedic applications of mesenchymal stem cell encapsulated and delivered for treatment of cartilage damage in joints. A therapeutic composition is prepared comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in microbeads of a three-dimensional biocompatible gel matrix. The hydrogel microbeads encapsulating stem cells maintain the viability and location of the stem cells for an extended period as compared to stem cells in suspension. The microbeads are implanted adjacent a target orthopedic treatment site where the microbeads allow the release of cellular factors from the encapsulated stem cells to surrounding orthopedic tissues to achieve desired therapeutic results such as healing of cartilage damage in joints. | 2012-04-12 |
20120087984 | STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS - Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such as a pharmaceutical agent, and at least one surface stabilizer. The component chemical compound exhibits chemical stability, even following prolonged storage, repeated freezing-thawing cycles, exposure to elevated temperatures, or exposure to non-physiological pH conditions. | 2012-04-12 |
20120087985 | SMALL PEPTIDE SEQUENCES FOR STABILIZING BIOMOLECULES - Disclosed herein are a class of small molecules, referred to as Small Peptide Sequences (SPS), that can stabilize biomolecules, particles containing the SPS and biomolecules, and compositions and methods of making the particles. The SPS are composed solely of amino acids common to humans and too small to trigger an immunological response (typically less than seven amino acids in total) and which will self assemble into particles sufficiently small to stay in liquid suspension at a first pH, typically a non-physiological pH, but which dissociate, releasing the biomolecule entrapped therein into solution, at a second pH, typically a physiological pH. The particles contain a SPS and a biomolecule, wherein the biomolecule is entrapped with the particle, immobilized on the surface of the particle, or combinations thereof. The particle releases the biomolecule upon contact with physiological fluids. | 2012-04-12 |
20120087986 | PHARMACEUTICAL FORMULATIONS COMPRISING DESVENLAFAXINE - Pharmaceutical formulations comprising desvenlafaxine, processes for preparing formulations comprising desvenlafaxine, and therapeutic uses and methods of treatment employing formulations comprising desvenlafaxine. | 2012-04-12 |
20120087987 | COMBINED USE OF TWO INSECTICIDES - The present disclosure relates to the combined use of two pesticides. A first pesticide composition provides an initial contact kill, and may form a barrier when applied to greasy surfaces. A second pesticide composition provides residual pesticidal activity on the surface. Methods of making and using the pesticide compositions are also provided. | 2012-04-12 |
20120087988 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY CONDITIONS USING PLATELET ENRICHED PLASMA - Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in particular, equines, by administration to the respiratory system. | 2012-04-12 |
20120087989 | USE OF GELLED PRP (PLATELET GEL) FOR VOLUMETRIC BREAST RECONSTRUCTION - The present invention relates to the application of a platelet gel for augmenting or restoring the volume of a soft tissue, particularly breast tissue, to biological implants comprising said gel, to a kit for preparing said implants and to a process for preparing said implants. | 2012-04-12 |
20120087990 | METHOD FOR PRODUCING ACTIVE HYDROGEN-DISSOLVED WATER AND APPARATUS FOR PRODUCING THE SAME - Provided are an apparatus and method for the long-term production of a drinking water in which active hydrogen is dissolved at a high concentration. | 2012-04-12 |
20120087991 | MUCOSITIS PREVENTION SUPPLEMENT AND TREATMENT - The present invention provides for a nutritional composition comprising from 0.25 g to 25 g of glutamine, in neutral or salt form or precursor or derivative thereof; and from 0.1 g to 10 g of a phytochemical or a mixture thereof, wherein the phytochemical is an antioxidant. The nutritional composition is particularly useful in the treatment and/or prevention of mucositis. | 2012-04-12 |
20120087992 | miRNAS AS THERAPEUTIC TARGETS IN CANCER - Methods for modulating expression of a component of a cell, comprising contacting the cell with a nucleic acid comprising an miR-140 nucleic acid sequence in an amount sufficient to modulate the cellular component are provided. Overexpression of miR-140 inhibits cell proliferation in both U-2 OS (wt-p53) and HCT 116 (wt-p53) cell lines. Cells transfected with miR-140 are more resistant to chemotherapeutic agent methotrexate, mi-140 expression is related to HDAC4 protein expression. The claimed methods reduce the protein expression level of HDAC4 without degrading the target mRNA. | 2012-04-12 |
20120087993 | BIOCIDAL ALDEHYDE COMPOSITION FOR OIL AND GAS EXTRACTION - A combination biocide (Glutaraldehyde or OPA), quaternary phosphonium biocide (preferably TTPC), alcohol (preferably isopropyl alcohol), and functional excipients for the oil and gas recovery industry. The functional excipients for the oil and gas recovery industry are a cellulose type proppant, a poloxamer wetting agent, a friction-reducing pluronic block copolymer, a drag reducing agent such as polyethylene oxide, and a flocculating agent. The OPA may be of the dialdehyde C | 2012-04-12 |
20120087994 | SYSTEMIC ADMINISTRATION OF NAC AS AN ADJUNCT IN THE TREATMENT OF BIOTERROR EXPOSURES SUCH AS SMALLPOX AND USE IN COMBINATION WITH DHEA FOR THE TREATMENT OF SMALLPOX - The invention is for the combination and related methods of N-acetyl-cysteine oral, inhaled, or intravenous, or glutathione inhaled or intravenous, generally in combination with antibiotic and/or antiviral therapy to ameliorate the toxic effects of infection with materials used in Bioterror incidents such as | 2012-04-12 |
20120087995 | NFAT Signal Inhibitor and Calcineurin Inhibitor - To provide a drug, an external use composition, and a cosmetic composition, which exhibit an NFAT signal inhibitory action, a calcineurin inhibitory action, and a hair growth-promoting effect. | 2012-04-12 |
20120087996 | ANTIOXIDANT SKIN CARE COMPOSITIONS - Antioxidant skin care composition comprising at least two antioxidant components one of which is a solid coffee extract antioxidant, which exhibits a synergistically increased antioxidant potency as measured by ORACsc compared to the antioxidant potency of antioxidant skin care compositions which do not contain at least two antioxidant components one of which is a solid coffee extract antioxidant. The skin care compositions are particularly suited for use in the treatment of wrinkles, pigmentation effects caused by sun damage and redness in the skin. | 2012-04-12 |
20120087997 | EDIBLE PRODUCTS WITH THERMOSTATIC AND COGNITIVE EFFECTS - An edible product for normalizing blood sugar levels is provided. The product includes a mulberry extract having a (w/w) flavonoids concentration of at least 10%, a 1-deoxynojirimycin (DNJ) concentration of about 2% and a GABA concentration of about 1% of the total amino acid content of said mulberry extract. | 2012-04-12 |
20120087998 | TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to compositions (including medicaments and nutritional products) for use in the prevention or treatment of Inflammatory Bowel Disease. Such compositions comprise a therapeutically effective amount of a soluble fibre derivable from fruit of the | 2012-04-12 |
20120087999 | INJECTION MOLDING MACHINE FOR TWO-MATERIAL MOLDING - It is an object to prevent dies from interfering with each other when the dies are closed and effectively prevent overshoot of cavity temperature while efficiently performing heating of the dies. In an injection molding machine for two-material molding including two sets of a first injecting unit and a second injecting unit that respectively plasticize different resin materials and inject and fill the resin materials, prior to performing injection molding on the first injecting unit side on a secondary side, after injection molding on the second injecting unit side on a primary side, heating of the dies is started before 180-degree rotation of a rotary die plate is completed. After the start of heating, until the 180-degree rotation of the rotary die plate is completed, i.e., die closing is performed, die temperatures are maintained within a temperature range set higher than die temperatures during the heating start and lower than die temperatures during injection. | 2012-04-12 |
20120088000 | DEVICE FOR PRODUCING CLOSURES - The invention relates to a device ( | 2012-04-12 |